India Digital Biomarkers Market Report 2023 to 2030

India Digital Biomarkers Market Analysis

$ 3999

India Digital Biomarkers Market was valued at $52.74 Mn in 2023 and is predicted to grow at a CAGR of 25.3% from 2023 to 2030, to $255.74 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic diseases, increasing smartphone penetration, government initiatives, and a growing focus on preventative care. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.

ID: IN10INDH158 CATEGORY: Digital Health GEOGRAPHY: India AUTHOR: Sarita Yadav

Buy Now

India Digital Biomarkers Market Executive Summary

India Digital Biomarkers Market was valued at $52.74 Mn in 2023 and is predicted to grow at a CAGR of 25.3% from 2023 to 2030, to $255.74 Mn by 2030.

Digital biomarkers are quantifiable physiological and behavioral data collected by digital devices like wearables and smartphones. They provide insights into health, including disease progression and treatment response, enabling continuous monitoring and real-time data collection. These biomarkers are used for various health conditions, such as diabetes, cardiovascular disorders, mental health issues, and neurodegenerative diseases. By tracking metrics like physical activity, heart rate, and sleep patterns, digital biomarkers help clinicians make informed decisions and support research with real-world evidence. As technology advances, their potential to transform healthcare and improve patient outcomes grows.

Nearly 42% of adults in India have at least one chronic disease, with hypertension affecting 27%, diabetes 12%, and arthritis 9%. The market therefore is driven by significant factors like the rising prevalence of chronic diseases, increasing smartphone penetration, government initiatives, and growing focus on preventative care. However, data privacy concerns, limited healthcare infrastructure, and limited integration with healthcare systems restrict the growth and potential of the market.

Prominent players in this field are ActiGraph LLC which specializes in wearable devices and data analytics for physical activity and sleep monitoring, contributing to clinical research through reliable digital biomarkers. AliveCor Inc. excels in portable ECG monitoring and AI-driven cardiac analysis, enhancing early diagnosis and intervention with FDA-cleared devices like KardiaMobile. Other contributors include Koneksa, and Altoida Inc. among others.

India Digital Biomarkers Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Rising Prevalence of Chronic Diseases: In India, 42% of adults have at least one chronic disease, including hypertension (25-30%), diabetes (12%), arthritis (9%), and significant cases of cancers and chronic respiratory diseases. This large population segment necessitates continuous medical care. The increasing prevalence of chronic conditions such as diabetes, heart disease, and cancer fuel the demand for digital biomarkers, crucial for early detection, monitoring, and management, thus driving market expansion.

Increasing Smartphone Penetration: India boasts a rapidly growing smartphone user base. This creates a large potential market for app-based digital biomarker solutions that leverage smartphone technology for data collection and analysis.

Government Initiatives: The Indian government actively promotes digital health initiatives through programs like "Ayushman Bharat" and the "National Digital Health Mission (NDHM)." These initiatives aim to improve healthcare accessibility and encourage the adoption of digital health solutions, including digital biomarkers.

Growing Focus on Preventative Care: There's an increasing emphasis on preventative healthcare in India. Digital biomarkers can empower individuals to take a more proactive approach to their health by tracking health indicators and identifying potential risks early on.

Market Restraints

Data Privacy Concerns: Data security and privacy are major concerns in India. Building trust with users regarding data collection, storage, and usage practices is crucial for market growth. The Personal Data Protection Bill (PDPB) is still under development, and stakeholders need to ensure compliance with evolving regulations.

Limited Healthcare Infrastructure: Disparities exist in healthcare infrastructure across different regions of India. This can limit access to digital biomarker technologies and expertise in some areas.

Limited Integration with Healthcare Systems: Seamlessly integrating digital biomarker data with existing healthcare information systems in India is crucial for optimal use by healthcare professionals. At present, this integration may be insufficient.

Regulatory Landscape and Reimbursement Scenario

In India, the regulatory landscape for digital biomarkers is primarily overseen by the Central Drugs Standard Control Organization (CDSCO), which classifies these tools under categories such as software as a medical device (SaMD) based on their functionality. The Department of Telemedicine (DoT) also plays a role in regulating telemedicine applications, intersecting with digital biomarkers used for remote patient monitoring. Stakeholders need to understand the specific classification of their digital biomarkers by the CDSCO to determine the appropriate regulatory pathway for approval. Additionally, compliance with India's emerging data privacy framework, particularly the draft Personal Data Protection Bill (PDPB), is critical for ensuring the legal handling of data collection, storage, and usage.

The reimbursement landscape for digital biomarkers in India is still developing. The National Health Insurance Scheme (NHIS), a government-funded program, currently offers limited coverage for medical devices, but digital biomarkers with strong clinical evidence and demonstrated cost-effectiveness may be considered for future inclusion. Meanwhile, private health insurance is gaining traction in India, with some insurers potentially offering coverage for specific digital health solutions that incorporate digital biomarkers, depending on the plan and technology involved.

Competitive Landscape

Key Players

Here are some of the major key players in the India Digital Biomarkers Market

ActiGraph LLC
AliveCor Inc.
Koneksa
Altoida Inc.
Amgen Inc.
Biogen Inc.
Empatica Inc.
Vivo Sense
IXICO plc
Adherium Limited

1. Executive Summary
1.1 Digital Health Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Digital Health Policy in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

India Digital Biomarkers Market Segmentation

By Type

Wearable
Mobile-based Applications
Sensors
Others

By Clinical Practice

Diagnostic digital biomarkers
Monitoring digital biomarkers
Predictive and Prognostic digital biomarkers
Other's (Safety, Pharmacodynamics/ Response, Susceptibility)

By Therapeutic Area

Cardiovascular and metabolic disorders (CVMD)
Respiratory disorders
Psychiatric disorders
Sleep & Movement Disease
Neurological disorders
Musculoskeletal disorders
Others (Diabetes, Pain Management)

By End-Use

Healthcare companies
Healthcare Providers
Payers
Others (Patients, caregivers)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.